SNPHF (Santen Pharmaceutical Co) Cash per Share: $1.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNPHF Santen Pharmaceutical Co Ltd SNPHF
71 GF Score
Price $13.05
GF Value $10.34
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Santen Pharmaceutical Co Cash per Share?

Santen Pharmaceutical Co SNPHF +4.40% 71 Cash per Share is $1.63 as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 71/100 and a GF Value™ of $10.34 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Santen Pharmaceutical Co's Cash per Share for the quarter that ended in Mar. 2026 was $1.63.

Santen Pharmaceutical Co  (OTCPK:SNPHF) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Santen Pharmaceutical Co Cash per Share Related Terms

Santen Pharmaceutical Co Cash per Share Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Cash per Share Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.78 1.17 1.75 1.85 1.63

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.85 1.77 1.38 1.31 1.63
SNPHF
71GF Score
Santen Pharmaceutical Co Ltd SNPHF
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Santen Pharmaceutical Co's Cash per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=525.262/322
=1.63

Santen Pharmaceutical Co's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=525.262/322
=1.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $1.63 mean?
Santen Pharmaceutical Co (SNPHF) has a Cash per Share of $1.63 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Cash per Share too high?
Santen Pharmaceutical Co's current Cash per Share is $1.63. Overall, Santen Pharmaceutical Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Cash per Share compare to LLY and JNJ?
Santen Pharmaceutical Co's Cash per Share of $1.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Drug Manufacturers company?
A good Cash per Share depends on the Drug Manufacturers industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Cash per Share is $1.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.34, compared to a current price of $13.05 — trading 26.2% above its estimated fair value. The current Cash per Share is $1.63. Santen Pharmaceutical Co's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Cash per Share is $1.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 26.2% above its estimated GF Value™ of $10.34. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Cash per Share: $1.63
  • GF Value™: $10.34 vs. price of $13.05 (26.2% above fair value)
  • GF Score™: 71/100 with 1 warning sign

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
71GF Score

Get the complete analysis for SNPHF

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.34
GF Value